Bial SA, of S. Mamede do Coronado, Portugal, and Tokyo-based Eisai Co. Ltd. reported data from their study 208 phase II trial testing Zebinix (eslicarbazepine acetate) in children ages 6-16 years old with focal-onset epilepsy at the 12th European Paediatric Neurology Society Congress in Lyon, France. Read More
Akari Therapeutics plc, of London, reported data for the first four patients in its ongoing phase II trial of Coversin in paroxysmal nocturnal hemoglobinuria (PNH). Read More
By using neutrophils to deliver liposome-encapsulated chemotherapy, researchers at the China Pharmaceutical University were able to significantly extend the survival of mice with recurrent glioblastomas. Read More
Provention Bio Inc., a young company advancing two phase II-ready assets from Janssen Research & Development LLC and a vaccine platform technology from Finland's Vactech Oy, has raised its first financing, $28.4 million, in a private placement of series A preferred stock that closed April 25. Provention will use proceeds of the offering to develop the assets through proof of concept. Read More
Proteostasis Therapeutics Inc., of Cambridge, Mass., filed an investigational new drug application with the FDA for PTI-808, its cystic fibrosis transmembrane conductance regulator potentiator. Read More
KARACHI, Pakistan – Despite strict laws by the Drug Regulatory Authority of Pakistan that make smuggling medicines into the country a crime punishable by a maximum sentence of 10 years' imprisonment, the problem remains rife. Read More
SAN DIEGO – After reporting upbeat data from the first part of an experiment with omaveloxolone for Friedreich's ataxia (FA), Reata Pharmaceuticals Inc. has adjusted the second part for better chances of continued victory, vice president of strategy Vineet Jindal told BioWorld at the BIO International Convention. Read More
SAN DIEGO – Nobody wants to get old. Health declines, disease increases and insurance costs skyrocket. But what if researchers could slow the process at the cellular level, reverting stem cells to their youthful state, or clearing senescent cells, a hallmark of advanced years? Read More
LONDON – Astellas Pharma Ltd.'s one-year suspension from the Association of the British Pharmaceutical Association (ABPI) has been extended for a further 12 months, with a warning that the company faces expulsion if further checks, due in October 2017, do not show compliance. Read More
Shares of Portola Pharmaceuticals Inc. (NASDAQ:PTLA) climbed 46.6 percent to close at $56.06 on Friday after the company won FDA approval for its once-daily factor Xa inhibitor, Bevyxxa (betrixaban), for the prevention of venous thromboembolism (VTE) in certain adults. Read More
Aveo Oncology Inc. CEO Michael Bailey told BioWorld that the positive opinion from the EMA's Committee for Medicinal Products for Human Use on approval of Fotivda (tivozanib) in advanced renal cell carcinoma is "really just the beginning" of the drug's revival. "It's a great first chapter," he said, to be followed by efforts for approval in North America and combination-drug experiments. Read More
